ERYTHROPOETIN AND INDICATORS SURVIVAL RATE OF ONCOHEMATOLOGIC AND ONCOLOGIC PATIENTS WITH ANAEMIC SYNDROME
DOI:
https://doi.org/10.30890/2567-5273.2022-23-01-011Keywords:
anaemia, anemia of malignant growth, blood, erythropoietin, survival rate.Abstract
Results of medical and biological investigations about the erythropoietin (EPO) nature, regulation of its production and mechanisms of its action are observed. Modern data about the synthesis of EPO and expression of EPO-receptors in nervous and somatic tMetrics
References
Андрияка А.А. Анемия злокачественного образования: особенности ведения пациентов. Гематология. Трансфузиология. Восточная Европа. 2018. №4(2), С.223 - 229.
Андрияка А.А. Негемопоэтические функции эритропоэтина. Гематология. Трансфузиология. Восточная Европа. 2018, №4(2). pp. 241 - 252.
Видиборець С., Борисенко Д. Діагностична цінність дослідження трансферину на різних стадіях розвитку анемії злоякісного новоутворення у пацієнтів із уротеліальним раком сечового міхура. World Science (Poland), 2019, №12(52), ч.1, С. 25-31. https://doi.org/10.31435/rsglobal_ws/30122019/6827
Видиборець С., Дерпак Ю., Кучер О., Горяінова Н. Трансфузійнотрансмісивні захворювання. Trends in the development of medicine, biology and pharmacy: collective monograph. Boston: Publisced by Primedia eLaunch, 2021. С. 126-166. Available at: https://doi.org/10.46299/ISG.2021.MONO.MED.1
Выдыборец С. В, Андрияка А. А. Современные принципы лечения анемии у пациентов с онкогематологическими и онкологическими заболеваниями. Гематология. Трансфузиология. Восточная Европа. 2016, №2(3). С. 388-396.
Новак В. Л., Масляк З. В,, Горяінова Н.В. і співавт. Показники діяльності гематологічної служби України в 2019 році. 2020. Львів, 52 с.
Федоренко З. П., Михайлович Ю. У., Гулак Л. О. і співавт. Рак в Україні, 2019-2020. Захворюваність, смертність, показники онкологічної допомоги. Бюлетень Національного регістру України. 2021. №22, 82 с. https://www.ncru.inf.ua
Aapro M., Barnadas A., Leonard R. C. et al. Effects of epoietin beta treatment in patients with metastatic breast cancer receiving chemotherapy. Results of BRAVE trial. 29th San Antonio Breast Cancer Symposium. Abstr 6079.
Aapro M., Coffier B., Dunst J. et al. Effect of treatment with epoetin beta on short-term tumour progression and sur¬ vival in anaemic patients with cancer: A meta-analysis. Br J Cancer. 2006. No 95. P.1467-1473.
Acs G., Acs P., Beckwith S. M. et al. Erythropoietin and erythropoietin recep¬tor expression in human cancer. Cancer Res. 2001. No 61. P. 3561-3565.
Anagnostou A., Liu Z., Steiner M. et al. Erythropoietin receptor mRNA express¬ sion in human endothelial cells. Proc Natl Acad Sci USA 1994. No 91. P.3974-3978.
Andriiaka A. Mechanisms of anemia formation in colorectal cancer, its clinical and laboratory characteristics. SWorld Journal (Bulgaria). 2021 (May), Issue 8, part 3. P.59-65. https://doi.org/10.30888/2663-5712.2021-08-03-087
Blajchman M. A., Vamvakas E. C. The continuing risk of transfusion-transmitted infections. N Engl J Med. 2006. No 355(13). P.1303-1305.
Boogaerts M., Oberhoff C., Ten Bockel-Huinink W. et al. Epoetin beta (NeoRecormon) therapy in patients with solid tumours receiving platinum and
non-platinum chemotherapy: a meta-analysis. Antnticancer Res. 2006. No 26.P.479-484.
Bokemeyer C., Aapro M.S., Courdi A. et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer. 2007. No 43. P.258—570.
Borysenko D., Vydyborets S. The main parameter of iron metabolism in patients with urothelial bladder cancer at different development stages of malignant neoplasm anemia. Scientific Journal of Polonia University Periodyk Naukowy Akademii Polonijnej. Czestochowa. 2020, Vol.43, No 6. P. 247-255. https://doi.org/10.23856/4330
Bray F., Ferlay J., Soerjomataram I., et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancer in 185 countries. CA Cancer J Clin. 2018. No 68. P.394-424. https://doi.org/10.3322/caac.21492
Busse L., Sinclair A., Rogers N. et al. Is Epo receptor over expressed in human tumor cells. Proc Am Assoc Cancer Res. 2005. No.46. Abstract 4562.
Caro J. J., Salas M., Ward A. et al. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer. 2001. No 91. P.2214-2221.
Carvalho G., Lefaucheur C., Cherbonier C. et al. Chemosensitization by erythropoietin through inhibition of the NF-kappaB rescue pathway. Oncogene. 2005. No 24. P.737-745.
Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue.
Semin Hematol. 1997. No 34(3 Suppl 2). P. 13-19.
Douglas R. J., Somerfield M. R., Hagerty K. L. et al., American Society of Hematology/American Society of Clinical Oncology 2007. Clinical practice guideline update on the use of epoetin and darbepoetin. Blood, 2007. No 1. P.1182-1192.
Ferlay J., Colombet M., Soerjomataram I., et al. Estimating the global cancer incidince and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019. No 144. P. 1941-1953. https://doi.org/10.102/ijc.31937
Gewirtz D. A., Walker T. D., Di X. et al. Influence of erythropoietin on sen¬sitivity to chemotherapeutic drugs in breast and leukemic tumor cells; implica-tions for erythropoietin use in cancer patients. Proc Amer Assoc Cancer Res. 2005. No 46. Abstract 41157.
Glaspy J., Bukowski R., Steinberg D. et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with non myeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol. 1997. No 15. P.1218-1234.
Goodnough L. T., Monk T. G., Andriole G. L. Erythropoietin therapy. N Engl J Med. 1997. No 336. P.933-938.
Greer J. P., Arber D. A., Glader B. et al. (Ed.) Wintrobe’s clinical hematology 13th ed., Philadelphia: Lippincott Williams & Wilkins, 2014. 2278 p.
Henke M., Laszig R., Rube С. et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet. 2003. No 362. P.1255-1260.
Lefebvre P., Vecerman F., Sarokham B. et al. Relationship between hemoglobin level and quality of life in anemic patients with chronic kidney disease receiving epoetin. Cur Med Res Opin. 2006. No 22. P.1929-1937.
Leyland-Jones B. Best Investigators and Study Group. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol. 2003. No 4(8). P.459-460.
Littlewood T. J., Bajetta E., Nortier J. W. et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a random¬ ized, double-blind, placebo-controlled trial. J Clin Oncol 2001. No 19. P.2865-2874.
Ludwig H., van Bells S., Barret-Lee P. et al The European Cancer Anaemia
Survey (ECAS): a large, multinational, prospective survey defining the preva¬
lence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer.
No 40. P.2293-2306.
Siegel R. L., Miller K. D., Fuchs H. E., Jemal A. Cancer Statistics 2021. CA. Cancer J Clin. 2021. No 71. P. 7-33. https://doi.org/10.3322/caas.21654
Sinclair A., Busse L., Arnold G. et al. Epo receptor transcription is not elevated nor predictive of surface expression in human tumor cells. Proc Assoc Cancer Res. 2005. No 46. Abstract 5457.
Turner J., Parsi M., Badireddy M. (2020) Anemia. StarPearls [Internet]. https://www.ncbi.nlm.nih.gov/books/NBK499994/
Van der Meer P., Lipcic E., Henning R. H. et al. Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure
after myocardial infarction. J Am Coll Cardiol. 2005. No 46. P.125-133.
Westenfelder C., Baranowski R. L. Erythropoietin stimulates proliferation of human renal carcinoma cells. Kidney Int. 2000. No 58. P.647-657.
Yildirim-Kahriman S. Non-intrinsic cancer risk factors. Exp Oncol. 2021. No 43(4). P. 290-297. https://doi.org/10/32471/exp-oncology.2312-8852.vol.43-no-4.16804
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Authors
This work is licensed under a Creative Commons Attribution 4.0 International License.
